Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22456351 | 0.89 | L3MBTL3 (0.34) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL26170660 | 0.85 | HRH3 (0.31) | HRH3 | |
| SCHEMBL22456352 | 0.85 | L3MBTL3 (0.42) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL24854441 | 0.82 | — | — | |
| SCHEMBL803511 | 0.79 | L3MBTL3 (0.38) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL20976850 | 0.78 | HRH3 (0.33) | HRH3L3MBTL3L3MBTL1 | |
| SCHEMBL13861719 | 0.78 | ALDH1A1 (0.41) | L3MBTL3L3MBTL1 | |
| SCHEMBL12026443 | 0.76 | HRH3 (0.34) | HRH3 | |
| SCHEMBL24940936 | 0.76 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1 | |
| SCHEMBL23594125 | 0.76 | OPRM1 (0.34) | HRH3L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759530-B2 | Method for producing phenoxypyridine derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20140011999-A1 | Method for Producing Phenoxypyridine Derivative | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-09 | — | — | US | disclosed |
| US-7531532-B2 | Hepatocyte growth factor receptor inhibitors; Antitumor agents, anticarcinogenic agents, angiogenesis inhibitors; pyrimidine derivatives like Pyrrolidine-1-carboxylic acid [6-(2-fluoro-4-{3-[2-(4-fluorophenyl)acetyl]thioureido}phenoxy)pyrimidin-4-yl]amide | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270421-A1 | Novel pyridine Derivative and Pyrimidine Derivative (1) | HGF, MET, FLT1 | HRH3 59/4885L3MBTL3 1125/4885L3MBTL1 1054/4885 |
| US-20140011999-A1 | Method for Producing Phenoxypyridine Derivative | QDPR, DRD4, DOT1L | HRH3 60/4885L3MBTL3 3512/4885L3MBTL1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.